SPIE SA : Volatility should make a big comeback
Entry price | Target | Stop-loss | Potential |
---|
€16.04 |
€17.2 |
€15.4 |
+7.23% |
---|
From a horizontal accumulation phase, the timing seems good to buy shares in SPIE and to get ahead of a break-out on the upside of the congestion area.
Summary● In a short-term perspective, the company has interesting fundamentals.
Strengths● The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.55 for the 2019 fiscal year.
● Sales forecast by analysts have been recently revised upwards.
● Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
● The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
● The stock is in a well-established, long-term rising trend above the technical support level at 14.27 EUR
Weaknesses● According to forecast, a sluggish sales growth is expected for the next fiscal years.
● The company has insufficient levels of profitability.
● For the last few months, analysts have been revising downwards their earnings forecast.
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.